Related Experiment Video
Updated: Apr 14, 2026
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
Published on: June 7, 2016
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular
Angelo Gámez-Pozo1, Julia Berges-Soria1, Jorge M Arevalillo2
1Molecular Oncology and Pathology Lab, Instituto de Genética Médica y Molecular-INGEMM, Instituto de Investigación Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Abstract:
Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies, leading to improved outcome. High-throughput technologies allow deepening into the molecular architecture of breast cancer, integrating different levels of information, which is important if it helps in making clinical decisions. microRNA (miRNA) and protein expression profiles were obtained from 71 estrogen receptor-positive (ER(+)) and 25 triple-negative breast cancer (TNBC) samples. RNA and proteins obtained from formalin-fixed, paraffin-embedded tumors were analyzed by RT-qPCR and LC/MS-MS, respectively. We applied probabilistic graphical models representing complex biologic systems as networks, confirming that ER(+) and TNBC subtypes are distinct biologic entities. The integration of miRNA and protein expression data unravels molecular processes that can be related to differences in the genesis and clinical evolution of these types of breast cancer. Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention.
Insights
This study reveals distinct molecular profiles for estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC). Integrating microRNA and protein data highlights TNBC
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Advances in breast cancer biology have enabled targeted therapies, improving patient outcomes.
- High-throughput technologies offer deeper insights into breast cancer's molecular complexity for clinical decision-making.
Purpose of the Study:
- To investigate and compare the molecular profiles of estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC) subtypes.
- To integrate microRNA (miRNA) and protein expression data to understand subtype-specific biological processes.
Main Methods:
- Analysis of miRNA and protein expression profiles from 71 ER+ and 25 TNBC formalin-fixed, paraffin-embedded tumor samples.
- Quantitative reverse transcription PCR (RT-qPCR) for RNA analysis and liquid chromatography-tandem mass spectrometry (LC/MS-MS) for protein analysis.
- Application of probabilistic graphical models to represent biological systems as networks and integrate multi-omics data.
Main Results:
- Probabilistic graphical models confirmed ER+ and TNBC as distinct biological entities.
- Integration of miRNA and protein data elucidated molecular processes linked to the genesis and clinical progression of breast cancer subtypes.
- TNBC exhibits a unique metabolic profile, suggesting potential therapeutic targets.
Conclusions:
- ER+ and TNBC breast cancer subtypes possess distinct molecular and biological characteristics.
- Multi-omics data integration is crucial for understanding subtype-specific breast cancer biology and clinical behavior.
- The identified unique metabolic profile of TNBC offers a promising avenue for developing novel therapeutic strategies.
